Search
Molsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnInterestingly, it is being studied as being a preventive measure in cerebral infarction [A31932]. … Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.
Succinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceuticalIt is also used in foods as a sequestrant, buffer, and a neutralizing agent. … A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalIt was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]
Cloxazolam
go.drugbank.com/drugs/DB01553ExperimentalAs well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis.
Diethyltoluamide
go.drugbank.com/drugs/DB11282ApprovedIt is widely used to repel biting pests such as mosquitoes and ticks.
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnThe organism was named _Streptomyces aureofaciens_ due to its gold-hued color. … It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow.
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigational[L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab]. … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.